A Phase 2 interventional study of Atibuclimab and Placebo in Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome and Acute Lung Injury, sponsored by Implicit Bioscience. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Implicit Bioscience · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 119th largest by planned enrollment of the 250 interventional ones that give a count, is one of 15 that started in 2026, is one of 74 in phase 2, reaches primary completion later than 45 of the 55 other live ones, and was the 295th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 7 days–30 days
Ohio State University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–72 hrs
Massachusetts General Hospital · Sites in United States
Ages 18–80
Indiana University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
324 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 101 · Phase 3 46 · Phase 4 6
First in 1991; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is close to the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 52 across the 250 interventional studies, 85 across the 68 observational. Of the 220 that completed or were terminated, 101 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 324 have an industry lead sponsor. The 10 most frequent:
Implicit Bioscience is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Implicit Bioscience has 3 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
20 of the studies in Respiratory Distress Syndrome with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05354141Phase 3Direct Biologics, LLCExtracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) | 2027-11-30 |
| NCT04369599Emory UniversityTrans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System | 2026-11 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.
The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
This is a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of anti-CD14 treatment with a recombinant chimeric monoclonal antibody (IC14) in hospitalized patients with Acute Respiratory Distress Syndrome (ARDS). CD14 is a key mediator in recognition of molecular markers of tissue damage (damage-associated molecular patterns, DAMPs) and infection (pathogen-associated molecular patterns, PAMPS).
The primary objective of the study is to determine the efficacy of IC14 in patients hospitalized with ARDS for reducing the severity of lung injury as measured by the day 4 Oxygenation Index (OI) assessed as a continuous measure (mean airway pressure x fraction of inspired oxygen [FiO2] x 100/partial pressure of oxygen [PaO2]). OI captures severity of hypoxemia and concurrent intensity of ventilatory support.
Secondary objectives include determining whether IC14 reduces the systemic and alveolar inflammatory response, and improves indices of oxygenation and illness severity. Exploratory endpoints include determining the effect of CD14 blockade on duration of mechanical ventilation and mortality in patients hospitalized with ARDS. Pharmacokinetic [PK]/Pharmacodynamic [PD] endpoints include determining day 4 IC14 levels in bronchoalveolar fluid (BALF) vs. serum, and determining the feasibility of measuring blood presepsin levels, a CD14-pathway specific biomarker for rapid assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients may be included in the study only if they meet all the following criteria:
Adult patients (18+) on mechanical ventilations with acute respiratory distress syndrome (ARDS) by Berlin Criteria (≤48 hours)
i. Common Risk Factors for ARDS: Pneumonia, aspiration, inhalation injury, pulmonary contusion, pulmonary vasculitis, drowning, non-pulmonary sepsis, major trauma, pancreatitis, severe burns, non-cardiogenic shock, drug overdose, multiple transfusions
Exclusion Criteria:
An individual fulfilling any of the following criteria should be excluded from enrollment in the study:
Significant pre-existing organ dysfunction prior to hospitalization
Presence of co-existing infection, including, but not limited to:
Bronchoscopy safety exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IC14 (atibuclimab) is a recombinant monoclonal antibody against human CD14
Biological: Atibuclimab
Sterile normal saline
Other: Placebo
monoclonal antibody against human CD14
Also known as: IC14
Sterile normal saline for injection
Day 4 Oxygenation Index
(mean airway pressure x fraction of inspired oxygen \[FiO2\] x100)/ partial pressure of oxygen \[PaO2\]
Time frame: Day 1 through Day 4
Biomarkers of injury and inflammation measured in bronchoalveolar lavage fluid
Interleukin(IL)-6
Time frame: Day 4
Biomarkers of injury and inflammation measured in plasma
Interleukin(IL)-6
Time frame: Day 4
Oxygenation index
(mean airway pressure x FiO2 x100)/PaO2
Time frame: Days 7 and 14
Oxygen saturation index
(mean airway pressure x FiO2 x100)/peripheral oxygen saturation \[SpO2\]
Time frame: Days 4, 7, and 14
P:F ratio
Ratio of partial pressure of arterial oxygen (P) to fraction of inspired oxygen (F)
Time frame: Days 4, 7, and 14
S:F ratio
Ratio of the arterial oxygen saturation (S) to fraction of inspired oxygen (F)
Time frame: Days 4, 7, and 14
Sequential Organ Failure Assessment (SOFA) Score (range 0 [best] to 24 [worst])
Disease severity scale
Time frame: Days 4, 7, and 14
Time to blood presepsin level
Time from study consent to measurement completion of blood presepsin level via the PATHFASTTM instrument
Time frame: Days 0-4
Cumulative incidence of run failures
Defined as not completing presepsin measurement between consent and infusion of study drug
Time frame: Days 0-1
Cumulative incidence of protocol-specified exempt serious events
protocol-specified exempt serious events
Time frame: Days 1-28
Cumulative incidence of grade 3 and 4 clinical and laboratory adverse events
Common Toxicity Criteria for Adverse Events version 5.0
Time frame: Days 1-28
Cumulative incidence of serious adverse events
Serious adverse events standard definition
Time frame: Days 1-28
Cumulative incidence of adverse events of special interest
Adverse events of special interest for test article and bronchoalveolar lavage
Time frame: Days 1-28
Ventilator-free Days
Days alive and free of invasive mechanical ventilation
Time frame: Days 1-28
Mortality
All-cause mortality
Time frame: Day 1-28
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Mar 2029, 32 months after the start.
Of 59 phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 32 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atibuclimab
Respiratory Distress Syndrome →
Implicit Bioscience